2-氯-5-甲基[1,6]萘啶 | 140692-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-氯-5-甲基[1,6]萘啶
• 中文别名: 2-氯-5-甲基-(口+奈)啶
• 英文名称: 2-chloro-5-methyl-1,6-naphthyridine
• CAS: 140692-93-9
• 化学式: C₉H₇ClN₂
• mdl: MFCD01443634
• 分子量: 178.621
• InChiKey: WRLQMYQERZRRTM-UHFFFAOYSA-N

物化性质

• 熔点：
  96～98℃
• 沸点：
  301.4±37.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氯-5-甲基[1,6]萘啶 在 吡啶 、 氨 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 2-bromo-N-(5-methyl-1,6-naphthyridin-2-yl)acetamide
  参考文献：
  名称：

  WO2008/144268

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氨基-3-戊烯-2-酮 在 五氯化磷 、 ammonium acetate 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 39.25h， 生成 2-氯-5-甲基[1,6]萘啶
  参考文献：
  名称：

  WO2008/144268

  摘要：

  公开号：

文献信息

• Pyridine and related aza heterocycle derivatives as cardiovascular agents
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0446604A3

  公开（公告）日：1992-02-19

  Novel pharmaceutical compounds and compositions having nitrogen containing ring systems which may be represented by the following structural formula: wherein R₁ or R₃ is a moiety of the formula: wherein R₆ is selected from either hydrogen or acetyl; R₇ is selected from 2, 3 or 4-pyridyl or 1-imidazolyl and Q is -(CH₂)n, where n is an integer from 1 to 5 and R₁ and R₂, R₂ and R₃, R₃ and R₄ or R₄ and R₅ taken together may be -CH=CH-CH=CH-. The compounds and compositions are useful as inhibitors of thromboxane synthetase and in the treatment of hypertension and arrythmia in mammals.

  具有含氮环系统的新型药物化合物和组合物，可以用以下结构式表示： 其中R₁或R₃是以下式的基团： 其中R₆从氢或乙酰中选择；R₇从2、3或4-吡啶基或1-咪唑基中选择，Q为-(CH₂)n，其中n是从1到5的整数，且R₁和R₂、R₂和R₃、R₃和R₄或R₄和R₅一起可能是-CH=CH-CH=CH-。这些化合物和组合物可用作血栓素合酶的抑制剂，并用于治疗哺乳动物的高血压和心律失常。
• UROTENSIN II RECEPTOR ANTAGONISTS
  申请人：Cook Brian Nicholas

  公开号：US20100121051A1

  公开（公告）日：2010-05-13

  Compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of Urotensin II with its receptor, including cardiovascular diseases. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds, and intermediates useful in these processes.

  式（I）的化合物，其中R1、R2、R3、R4、R5、R6、W和Y如本文所述，或其互变异构体、前药、溶剂化物或盐。这些化合物可用作Urotensin II的抑制剂，因此可用于治疗多种通过Urotensin II与其受体的相互作用介导或维持的疾病和障碍，包括心血管疾病。本发明还涉及包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1
  申请人：Claremon David A.

  公开号：US20110112062A1

  公开（公告）日：2011-05-12

  This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 V1, V1a, VIb, VII, Vi1a, VIIb, VIII, V111a, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  本发明涉及公式 I、II、III、IHa、NIb、IV、IVa、IVb、IVc、IVd、IVe、V、Va、Vb1、V1、V1a、VIb、VII、Vi1a、VIIb、VIII、V111a、VIIIb、IX、IXa、X 和 Xa 的新化合物，其药学上可接受的盐以及其制备的药物组合物，用于治疗与哺乳动物中 11 β-HSD1 调节或抑制相关的疾病。本发明还涉及所述新化合物的药物组合物和在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Claremon David A.

  公开号：US20130244994A1

  公开（公告）日：2013-09-19

  This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及公式(I)的新化合物及其药学上可接受的盐和药物组合物，用于治疗与哺乳动物中11β-HSD1的调节或抑制有关的疾病。本发明还涉及公式(I)的新化合物的药物组合物以及它们在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法的使用。
• Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones
  作者：Baldev Singh、George Y. Lesher、Kevin C. Pluncket、Edward D. Pagani、Donald C. Bode、Ross G. Bentley、Mary J. Connell、Linda T. Hamel、Paul J. Silver

  DOI：10.1021/jm00104a012

  日期：1992.12

  Two series of medorinone (3) analogs were prepared by modifications at C(2) and C(5). The C(2)-series was prepared from 2-chloro-5-methyl-1,6-naphthyridine (4) by replacement of the chloro group with various nucleophiles. The C(5)-series was prepared from 5-acyl-6-[2-(dimethylamino)ethenyl]-2-(1H)-pyridinone (11), 5-bromo-1,6-naphthyridin-2(1H)-one (17), and 1,3-diketones 19 and 27. 1,6-Naphthyridin-2(1H)-ones are novel inhibitors of cAMP PDE III. Modification of the carbonyl group of 3 or N-methylation at N(1) resulted in a dramatic loss of enzyme activity. Absence of the C(5)-methyl group of medorinone (3) or its shift to C(3) or C(7) also resulted in reduced activity. Substitution at C(3) also diminished activity. However, substitution at C(5) by a wide variety of substituents led to improvement of enzyme activity and several C(5)-substituted analogs were more potent than milrinone.